Sort   by:  
 Page size 
GenomicPharmacogenetics of Efavirenz Discontinuation for Reported CNS Symptoms

This is an evaluation of genetic associations with efavirenz (EFV) discontinuation for central nervous system (CNS) symptoms within 12 months of treatment. Patients were treated at an HIV primary care clinic in Nashville TN from 1998 to 2012. Previously known SNPs in

phs001253 | dbGaP
GenomicPharmacogenomics of HIV Therapy - Atazanavir Bilirubin-related Side Effects

This is an evaluation of genetic associations with atazanavir (ATV) discontinuation for bilirubin-related causes within 12 months of treatment. Patients were treated at an HIV primary care clinic in Nashville TN from 1998 to 2012. A previously known SNP in UGT1A1 (rs887829) was used to define met...

phs001484 | dbGaP
TranscriptomicsPemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma
We devised a high-throughput, cell-based assay to identify novel therapeutic compounds to treat Group3 medulloblastoma (G3 MB). Mouse G3 MBs, grown as neurospheres, were screened against a library of approximately 7,000 compounds including FDA-approved drugs. We identified two FDA-approved drugs, ...
ORGANISM(S): Mus musculus 
2014-04-15 | E-GEOD-46406 | biostudies-arrayexpress
UnknownMEDULLOBLASTOMA
Not available
S-EPMC4046290 | biostudies-literature
Sort   by:  
 Page size